Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen people ask about changes to their bum before and after Mounjaro, most expect a straightforward 'yes it shrinks, here's proof' answer. The reality is more interesting and more nuanced. Tirzepatide drives meaningful fat loss across the whole body, but where fat comes from first, and how muscle responds, depends on factors your prescriber can help you plan around. These are prescription-only medicines; any discussion of whether treatment is right for you is a clinical decision, not one to make from a search result alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The biggest misconception around weight loss and body shape is that you can meaningfully direct where fat comes from. Mounjaro doesn't spot-reduce the bum, the stomach or anywhere else. What tirzepatide does is create a sustained calorie deficit by reducing appetite and slowing gastric emptying, acting on both GIP and GLP-1 receptors in a way no other licensed UK weight-loss medicine currently matches. Your body then draws on fat stores from across its surface and internally, the order is largely decided by your genetics and hormonal profile, not by the medicine.
That matters practically. Some people find their waist reduces noticeably before their hips and thighs shift. Others see the opposite. Neither pattern means the treatment isn't working, and neither can be reliably predicted in advance. The full picture of weight-loss changes on Mounjaro consistently shows reductions across multiple body regions as treatment continues at higher doses, which is the more clinically meaningful frame than any single area in isolation.
The NHS guidance on tirzepatide notes that treatment is intended to be part of a programme including a reduced-calorie diet and increased physical activity, the NHS medicines page for tirzepatide summarises this alongside what the medicine does and its common side effects. That lifestyle context shapes body composition outcomes as much as the medicine does.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and recorded average weight reductions of around 20–21% at the 15mg dose over 72 weeks. Total fat mass fell substantially across the cohort. Importantly, where body-composition sub-analyses have been performed in the tirzepatide programme, lean mass tends to be partially preserved relative to total mass lost, but it is not immune. Participants who lost weight rapidly or who ate too little protein lost more lean tissue alongside fat.
For the gluteal area specifically, this means the practical outcome varies. Fat under and around the buttocks reduces over time, often noticeably so. If the gluteal muscles are not being worked and protein is inadequate, some people find the region loses both fat and muscle, producing a flatter appearance. If resistance training targeting the glutes is maintained and protein targets are met (typically 1.2–1.6 g per kg of body weight is the professional recommendation) many people preserve or even improve gluteal muscle definition as fat recedes. This is an area where input from a physiotherapist or dietitian alongside your prescriber makes a real difference.
Questions about how quickly these changes become visible are reasonable. Most people find the pace matters as much as the direction, and how long Mounjaro takes to work has a practical bearing on body composition planning, including what to do in the early weeks on the starter dose.
Skin laxity (loose or crepey skin) in the gluteal area after substantial weight loss is common and is not caused by the medicine. It results from the skin's elastic fibres being stretched over time and then, as the underlying fat reduces, having less to fill against. The pace of loss plays a role: very rapid loss gives skin less time to adapt. Age and genetics are the primary determinants of how much snap the skin retains.
There is no licensed topical treatment that reverses established skin laxity, despite the confident claims of many cosmetic products. Keeping the skin hydrated, maintaining muscle beneath it through strength work, and ensuring overall nutrition supports collagen turnover are all sensible habits, none guarantees a specific outcome. People who have lost a large percentage of body weight sometimes consider surgical options once weight has stabilised, but that is a separate conversation with a plastic surgeon, well outside the scope of a weight-loss medicine.
If you are mid-treatment and noticing changes, the changes that typically appear by one month and the longer arcs visible in broader before-and-after accounts can give context for where you are in the process. For men specifically, gluteal fat distribution tends to differ, and how Mounjaro affects body shape in men covers those patterns separately.
Tirzepatide is a prescription-only medicine, and a prescriber assesses every person individually before treatment begins, BMI alone doesn't determine suitability. Adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure or type 2 diabetes, may be eligible, subject to a full clinical review. Lower thresholds can apply for some ethnic backgrounds under UK guidance.
At a service like nume, the process starts with a free consultation reviewed by a GPhC-registered prescriber, a real clinician, same day. Orders placed before 12pm on a weekday, once clinically approved, are dispatched the same day. It's a practical detail that matters if you're planning around a busy week: a Monday order placed in the morning arrives Tuesday. The treatment comes in plain, unbranded packaging via tracked DPD delivery, with prescriber aftercare available seven days a week.
Thinking about whether treatment is right for you is worth doing carefully, with accurate information. The tirzepatide treatment overview covers the full licence, the dose schedule and the clinical context. A cost overview is available on the treatments page, where you can also check eligibility and start the process if it looks right for your situation.
The changes people notice in body shape, including the gluteal area, are real and for many people significant. The evidence supports that. Getting there safely and with good muscle retention is a question of doing it with proper clinical support alongside lifestyle changes, not of choosing the right medicine and hoping for the best on its own.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.